DHR Health Institute for Research and Development Acquires Mobile Research Unit to Treat COVID-19 Patients

Mobile unit to help identify and evaluate potential treatments for non-hospitalized adults with COVID-19

Translate to Spanish or other 102 languages!

Delievery of the Mobile Research Unit

Mega Doctor News

- Advertisement -

Edinburg, Texas – DHR Health Institute for Research and Development announces the arrival of the National Institutes of Health (NIH) Sponsored Mobile Research Unit.  DHR Health Institute for Research and Development is one of nine to be granted a unit by the NIH, allowing the institute to continue their mission to treat COVID-19 patients in the Rio Grande Valley. 

“We are extremely excited to partner with NIH in this initiative and to be only 1 of 9 sites in the US that has been granted by NIH with such capacity-building initiative,” said Sohail Rao, executive vice president, DHR Health and president and CEO DHR Health Institute. “The Mobile Research Unit will be used to enroll thousands of patients and volunteers in large scale clinical trials testing a variety of investigational vaccine, monoclonal antibodies and drugs intended to protect people from COVID-19 and/or treat them for acute and chronic complications of COVID-19”

Through the acquirement of the Mobile Research Unit, DHR Health Institute for Research and Development will expand the capacity to conduct innovative clinical trials that would benefit the residents of the Rio Grande Valley and treat them for chronic complications of COVID-19.  The 38×11.5 unit, that features a nurse practitioner, research nurse coordinator, driver/coordinator, three exam rooms and a lobby, will have access to enroll thousands of patients and volunteers in large clinical trials, testing a variety of investigational vaccines, monoclonal antibodies, and drugs intended to protect people from COVID-19. 

- Advertisement -

The DHR Health Institute for Research and Development is committed to providing access to innovative and advanced clinical care for patients in the Rio Grande Valley and currently has four clinical trials that will be initiated in the mobile unit immediately while other trials are being negotiated.  Committed to enrolling individuals most impacted by COVID-19, DHR Health Institute for Research and Development will work closely with the community to make participation in the trial available to those who qualify for clinical research.  In addition to a modest stipend, transportation services are also available for patients who would like to participate.

For more information about participating in a study, please call DHR Health Institute for Research and Development at 956-362-2393 or visit DHRResearch.org

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

FDA Approves Immunotherapy Regimen Studied by Mayo Clinic for Stage 3 Colon Cancer

The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for some patients with stage 3 colon cancer following surgery. The treatment is for patients whose tumors have deficient DNA mismatch repair, or dMMR.

Domestic Violence Claims 160 Lives in Texas During 2025, New Report Reveals

Domestic violence claimed the lives of 160 Texans in 2025, according to a report released October 1, 2026, by the Texas Council on Family Violence (TCFV), documenting the continuing impact of intimate partner violence across the state.

Over $20 Million In Career Training Grants Awarded Across Texas

Governor Greg Abbott announced 84 Jobs and Education for Texans (JET) grants totaling over $20 million have been awarded to Texas public junior, state, and technical colleges; school districts; and open-enrollment charter schools.

STC Students Make History as Driscoll RGV’s First Respiratory Therapy Student Hires

South Texas College Respiratory Therapy students are getting an early start in pediatric care after being selected for Driscoll Children’s Hospital Rio Grande Valley’s inaugural Student Respiratory Tech positions.
- Advertisement -